Dialysis independence for a young patient with refractory multiple myeloma treated with teclistamab: A case report.

Teclistamab, a B-cell maturation antigen-targeting bispecific antibody, offers a promising treatment option for relapsed/refractory multiple myeloma (RRMM), even in patients with severe renal impairment. The present study describes the case of a 47-year-old woman with RRMM who achieved minimal residual disease negativity and dialysis independence following teclistamab treatment. Despite prior resistance to multiple therapies, including an anti-CD38 monoclonal antibody (daratumumab), two proteasome inhibitors (bortezomib and carfilzomib), an immunomodulatory drug (lenalidomide), an exportin 1 inhibitor (selinexor), a BCL-2 inhibitor (venetoclax) and dexamethasone, and post-autologous stem cell transplantation relapse, teclistamab induced a deep hematological response. Cytokine release syndrome was manageable and no major complications occurred. The present case highlights the feasibility and effectiveness of teclistamab in patients with end-stage renal disease.